Detalle Publicación

ARTÍCULO

SEOM clinical guideline for the management of malignant melanoma (2017)

Autores: Berrocal, A. (Autor de correspondencia); Arance, A.; Castellon, VE.; de la Cruz, L. ; Espinosa, E.; Cao, M. G.; Larriba, JLG. ; Marquez-Rodas, I. ; Soria, A.; Martín Algarra, Salvador
Título de la revista: CLINICAL AND TRANSLATIONAL ONCOLOGY
ISSN: 1699-048X
Volumen: 20
Número: 1
Páginas: 69 - 74
Fecha de publicación: 2018
Resumen:
All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.
DOI: https://doi.org/10.1007/s12094-017-1768-1
Impacto:
16 citas en
Google Scholar